172 related articles for article (PubMed ID: 34264473)
1. Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
Yoshida T; Morimoto K; Kaburagi N; Fujino T; Takemitsu TY; Yamashita N; Oya M
Int Urol Nephrol; 2022 Apr; 54(4):861-872. PubMed ID: 34264473
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients.
Minakuchi H; Yoshida T; Kaburagi N; Fujino T; Endo S; Takemitsu TY; Yamashita N; Itoh H; Oya M
Ren Fail; 2020 Nov; 42(1):799-806. PubMed ID: 32779954
[TBL] [Abstract][Full Text] [Related]
3. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
5. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
Covic AC; Floege J; Ketteler M; Sprague SM; Lisk L; Rakov V; Rastogi A
Nephrol Dial Transplant; 2017 Aug; 32(8):1330-1338. PubMed ID: 27342579
[TBL] [Abstract][Full Text] [Related]
6. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.
Greenbaum LA; Jeck N; Klaus G; Fila M; Stoica C; Fathallah-Shaykh S; Paredes A; Wickman L; Nelson R; Swinford RD; Abitbol CL; Balgradean M; Jankauskiene A; Perrin A; Enoiu M; Ahn SY
Pediatr Nephrol; 2021 May; 36(5):1233-1244. PubMed ID: 33106892
[TBL] [Abstract][Full Text] [Related]
8. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
[TBL] [Abstract][Full Text] [Related]
9. Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.
Otsuki T; Utsunomiya K; Moriuchi M; Horikoshi S; Okamura M; Suzuki H; Okamura M; Maruyama N; Shibahara N; Abe M
Nephron; 2018; 140(3):161-168. PubMed ID: 29991053
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study.
Bajo MA; Ríos-Moreno F; Arenas MD; Devesa-Such RJ; Molina-Higueras MJ; Delgado M; Molina P; García-Fernández N; Martin-Malo A; Peiró-Jordán R; Cannata-Andia J; Martín-De Francisco ÁL;
Nefrologia (Engl Ed); 2022; 42(5):594-606. PubMed ID: 36739246
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
[TBL] [Abstract][Full Text] [Related]
12. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Schmid H; Lederer SR
Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
[TBL] [Abstract][Full Text] [Related]
14. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
[TBL] [Abstract][Full Text] [Related]
15. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Floege J
Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
[TBL] [Abstract][Full Text] [Related]
16. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Ketteler M
Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
[TBL] [Abstract][Full Text] [Related]
17. Next-generation phosphate binders: focus on iron-based binders.
Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
Sprague SM; Ketteler M; Covic AC; Floege J; Rakov V; Walpen S; Rastogi A
Hemodial Int; 2018 Oct; 22(4):480-491. PubMed ID: 29656600
[TBL] [Abstract][Full Text] [Related]
19. Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation.
Floege J; Funk F; Ketteler M; Rastogi A; Walpen S; Covic AC; Sprague SM
Nephrol Dial Transplant; 2020 Jun; 35(6):946-954. PubMed ID: 32259248
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study.
Liu J; Zuo L; Walpen S; Bernard L; Marty M; Enoiu M
Nephron; 2024; 148(1):22-33. PubMed ID: 37473746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
